Insights & news

European Commission Launches Public Consultation on Pharmaceutical Strategy for Europe

  • 17/06/2020
  • Articles

The European Commission (the Commission) launched on 16 June 2020 a public consultation on its Pharmaceutical Strategy for Europe (the PSE) which will run until 15 September 2020 (see, attached press release and questionnaire). The consultation targets a broad audience of patient associations, industry, public authorities, academia and the general public for views on issues of access to medicines; availability and affordability of medicines; European autonomy and production of medicines; innovation; and environmental sustainability.
The questionnaire raises important and at times controversial issues in probing for 

  • the reasons for medicine shortages;
  • the possible need for a link between an EU-wide marketing authorisation and the requirement to make the medicine available throughout the EU;
  • justifications for medicine prices;
  • actions supportive of R&D of innovative medicines and cures for unmet medical needs;
  • risks and opportunities of digital technologies such as artificial intelligence and use of real world data.  

The Commission had already started another consultation on the Roadmap for the PSE which will be open until 7 July 2020 (see, Van Bael & Bellis Life Sciences News Alert of 3 June 2020). The Roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *